OutSee

OutSee is a Cambridge-based genomics and drug discovery company founded as a University of Cambridge spinout. It was created to address a fundamental limitation in how the pharmaceutical industry discovers drug targets: most existing approaches rely on pattern-matching known genetic associations across large datasets, which means they miss the underlying biological mechanisms that actually drive disease. OutSee's founding insight was that a different approach — one that reasons directly from the molecular biology of the genome — could uncover targets that conventional methods would never find.

The company's proprietary technology, Nomaly, is a hypothesis-free AI engine that predicts disease and phenotype directly from a single genome. Unlike conventional tools, it does not require large datasets or pre-existing associations; it can be applied to small datasets and can unlock new insights from data that has already been analysed. Nomaly has broad applicability across disease areas, with OutSee's in-house programme initially focused on CNS, rare, and metabolic diseases. The company has partnered with Genomics England and FinnGen, demonstrating the technology's relevance to real-world patient stratification and target identification programmes.

OutSee has received over £500,000 in Innovate UK precision medicine grants to support Nomaly's development and its application to dementia research. In 2025 the company raised £1.8 million in a seed round led by Ahren Innovation Capital, with participation from Kadmos Capital, Empirical Ventures, and Panacea Ventures, to expand its in-house target pipeline and establish new partnerships with major pharma and biotech companies.